LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Allogene Therapeutics Inc

Затворен

СекторЗдравеопазване

1.43 11.72

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.3

Максимум

1.46

Ключови измерители

By Trading Economics

Приходи

206K

-60M

EPS

-0.28

Марж на печалбата

272,450

Служители

226

EBITDA

-302K

-56M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+500.78% upside

Дивиденти

By Dow Jones

Следващи печалби

6.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

22M

278M

Предишно отваряне

-10.29

Предишно затваряне

1.43

Настроения в новините

By Acuity

60%

40%

334 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Allogene Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.06.2025 г., 14:31 ч. UTC

Печалби

New York State Retirement Fund Posts 5.84% Annual Investment Return

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 20:33 ч. UTC

Печалби

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 19:36 ч. UTC

Пазарно говорене

Oil Futures Post Solid Weekly Gains -- Market Talk

6.06.2025 г., 19:28 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6.06.2025 г., 18:46 ч. UTC

Пазарно говорене

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6.06.2025 г., 18:02 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Continues to Decline -- Market Talk

6.06.2025 г., 16:35 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:34 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:21 ч. UTC

Пазарно говорене

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

6.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6.06.2025 г., 15:53 ч. UTC

Пазарно говорене

Mexican Inflation Seen Rising in May -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6.06.2025 г., 15:16 ч. UTC

Пазарно говорене

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6.06.2025 г., 15:05 ч. UTC

Пазарно говорене

Silver at its Highest In Nearly 15 Years -- Market Talk

6.06.2025 г., 14:35 ч. UTC

Пазарно говорене

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6.06.2025 г., 14:15 ч. UTC

Пазарно говорене

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6.06.2025 г., 14:12 ч. UTC

Печалби

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6.06.2025 г., 14:09 ч. UTC

Печалби

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Allogene Therapeutics Inc Прогноза

Ценова цел

By TipRanks

500.78% нагоре

12-месечна прогноза

Среден 7.75 USD  500.78%

Висок 14 USD

Нисък 2.5 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Allogene Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

10

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

1.18 / 1.69Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

334 / 380 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.